3药方案在局部晚期、复发或转移头颈鳞癌中的研究  

The research of three-drug therapy in locally advanced,recurrent or metasis head and neck squamous cell cancer

作　　者：赵越[1] 林楷[1] 林静[2] 卜庆[2] 

机构地区：[1]桂林医学院研究生学院,广西桂林541004 [2]桂林医学院附属医院肿瘤内科,广西桂林541001

出　　处：《华夏医学》2015年第6期38-41,共4页Acta Medicinae Sinica

摘　　要：目的:比较多西他赛+顺铂+替吉奥、多西他赛+顺铂、顺铂+替吉奥3种化疗方案治疗局部晚期、复发或转移头颈鳞癌的疗效及不良反应。方法:回顾性分析我院肿瘤内科2009年1月至2015年5月122例局部晚期、复发或转移头颈鳞癌患者的临床资料,比较3组化疗方案的疗效及不良反应。结果:3组化疗的有效率及疾病控制率分别为66.67%,86.67%;36.36%,65.91%和33.33%,62.50%;无病进展期(PFS/d)分别为(201.00±82.74)d,(130.00±90.95)d,(100.00±58.64)d,3药方案显著高于2药方案(P<0.05)。3种方案严重不良反应的发生率无统计学差异(P>0.05),且患者均可耐受。结论:多西他赛+顺铂+替吉奥方案的近期疗效和远期疗效明显比多西他赛+顺铂及顺铂+替吉奥方案好,且不良反应均可耐受,可作为头颈鳞癌化疗的首选方案。Objective：To compare the effect and toxicity of docetaxel＋cisplatin＋ S-1,docetaxel＋cisplatin and cisplatin＋S-1chemotherapy in head and neck squamous cell cancer,respectively.Methods：Collected locally advanced,recurrent or metasis head and neck squamous cell cancer 122patients’ data of Medical Oncology in Affiliated Hospital of Guilin Medical University during January 2009 and May 2015 and compared the efficacy and toxicity of the three groups.Results：The effective rate and disease control rate were 66.67%,86.67% and 36.36%,65.91% and 33.33%,62.50%,respectively and progression-free survival（PFS/d）was（201.00±82.74）d,（130.00±90.95）d,（100.00±58.64）d,respectively.Three-drug therapy was significantly higher than that of two-drug therapy（P〈0.05）.The side-effects of these three kinds of programs were not statistically significant（P 〉 0.05）and patients could tolerate well.Conclusion：The short-term efficacy and long-term efficacy in docetaxel＋ cisplatin ＋ compound tegafur regimen was significantly better than that of docetaxel＋ cisplatin and cisplatin ＋ compound tegafur,and toxicity can be tolerated well.It can be the first choice in head and neck squamous cell cancer.

关 键 词：头颈鳞癌 多西他赛 顺铂 替吉奥 

分 类 号：R739.6[医药卫生—肿瘤]